Ritter Pharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: Los Angeles CA United States (2004)
Status: Acquired by Qualigen (2020)

Organization Overview

First Clinical Trial
2011
NCT01113619
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ritter Pharmaceuticals | Ritter Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

alpha-galacto-oligosaccharides (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lactose Intolerance (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1